London, November 26, 2020 / PRNewswire / – Haoma Medica today announced the completion of the first human-trial for NaQuinate, a naphthoquinone carboxylic acid, which is being developed as an orally administered therapeutic for osteoporosis.
A first-in-human trial initiated last year in healthy adults studied single and multiple doses of NaQuinate. The primary objective was to assess safety, tolerability, and pharmacokinetics.
“We are delighted that the first human studies have completed their final dose. There was no significant safety or tolerability concern for testing at the highest dose that underscores our expectation that Naquinate is safe and well tolerated, ”Dr. Senk Oguz, Chief Medical Officer of Homa Medica.
“Our pre-clinical research has revealed an exciting feature of NaQuinate, where it appears to be the body’s ability to work in a harmonious manner with the natural response to bone formation when and where necessary. Enhances the natural response to weight gain exercise – which is now a ‘smart will’ drug, ‘Dr. Steve deacon, CEO of Hyoma Medica “Together with safety data from this first-in-human study, it supports the ability that NaQuinate treatment can provide a safe, novel and smart therapeutic approach to bone disorders such as bone disorders and improve healthy skeletal lifespan Can keep. “
Previous studies have shown NaQuinate to protect against bone quality and quantity reduction occurring in response to ovariectomy in rodent models. In the mechanical mouse loading model, NaQuinate, a surrogate for weight-bearing exercise, synergistically enhanced the body’s normal response to load by forming bone, targeting relevant cortical bone areas. This synergistic interaction between NaQuinate and mechanical loading suggests the functional use of bone mechanostat, a term that describes how mechanical loading affects bone structure in the regulation of bone structure and architecture. NaQuinate is currently being evaluated using a curative model of osteoporosis versus bisphosphonate and loading model versus anabolic; The result is expected early next year.
Osteoporosis is a silent disease that often does not present with any signs or symptoms until a fracture occurs. It thus remains a rudimentary and controllable disease.
Osteoporosis results in bone loss and changes in bone quality and strength that occur through a normal aging process that makes bones weak. Fragile bones fracture, which progresses into a downward spiral of disability, loss of independence and increased mortality with considerable social and economic burden. Fragility fracture is a major obstacle to healthy aging. A fragile fracture occurs every 3 seconds worldwide.
According to the International Osteoporosis Foundation, there are approximately 200 million sufferers of the disease worldwide. The combined lifetime risk of fracture is 40% and is equivalent to the risk of heart disease. In women over the age of 45, osteoporosis results in longer hospital stays, such as many other diseases such as breast cancer, heart attacks, and diabetes.
About homa medica
Hyoma Medica is a clinical-stage biotechnology company focused on the development of therapeutics to maintain bone and vascular health.
for more information please visit www.haomamedica.com
Investor Relations Contact:
Name: Carmen Greco
E-mail: [email protected]
Content is by PR Newswire. Tech Media is not responsible for the content provided or any link related to this content. Tech Media is not responsible for the accuracy, timeliness or quality of content.